Stem Cell–Derived Neural Progenitors Show Distinct Biological Effects in Progressive MS
A new study found that repeated spinal-fluid injections of patients’ own mesenchymal stem cell–derived neural progenitor cells produced consistent changes in four cerebrospinal-fluid biomarkers in people with progressive multiple sclerosis, suggesting the treatment has measurable biological effects within the central nervous system. While the findings may help researchers track treatment response and refine future trials, they do not yet demonstrate that the experimental therapy slows disability progression or restores neurological function.